How Can Innovation Remain Affordable?
-
Elisabeth-Herz-Kremenak-Saal
Plenary
/
in deutscher SpracheExpensive innovations in medication and precision medicine are placing strain upon our solidarity-based healthcare systems. What are our priorities? Which benefits should (not) be offered?
| |||||
| |||||
| |||||
| |||||
|
Thomas GEBAUER
Executive Director, Stiftung Medico International, Frankfurt
| 1979-1986 | Programme Officer for Latin America, Medico International e.V., Frankfurt/Mexico |
| 1987-1995 | Head, Project Department, Medico International e.V., Frankfurt |
| 1996-2018 | Executive Director, Medico International e.V., Frankfurt |
| since 2019 | Executive Director, Stiftung Medico International, Frankfurt |
Dr. Peter NEUBECK
Partner, Kurma Partners SA, Munich
| Dr. Peter Neubeck is a Medical Doctor, educated at Ludwig-Maximilians-Universität in Munich as well as Harvard Medical School and holds an MBA from INSEAD. After tenures at Großhadern University Clinic, Cleveland Clinic, and Beth Israel Deaconess Hospital followed by McKinsey & Company and several leadership positions at Novartis, he entered the Venture Capital industry. He took on responsibilities as an Investment Manager and collected valuable operations experience in various executive roles. Since January 2019 he heads the investment business of Kurma Partners in Germany. |
Dr.in phil. Sigrid PILZ
Nursing and Patient Advocate, Vienna
| Studium der Erziehungswissenschaften und Psychologie, Universität Innsbruck | |
| 1985-2012 | Beamtin, Bundesministerium für Familien und Jugend als Leiterin, Abteilung für Internationale Familien- und Jugendpolitik |
| Lektorin, Institut für Erziehungswissenschaften, Universität Innsbruck | |
| 2001-2012 | Gesundheitssprecherin der Wiener Grünen, Grüne Gesundheitspolitikerin im Wiener Landtag und Gemeinderat |
| Seit 2012 Wiener Pflege-, Patientinnen- und Patientenanwältin |
Mag. Sabine RADL
Commercial Head Established Products Mature Markets, SANOFI, Vienna
| 1994-2001 | Sales&Markekting, BUM, JohnsonJohnson Medical, Vienna |
| 2002-2004 | Commercial Manager CEE, Wyeth CEE, Vienna |
| 2004-2008 | Area Manager CEE, Ranbaxy CEE, Vienna |
| 2008-2011 | Managing Director, Ranbaxy Germany |
| 2011-2013 | General Manager Zentiva and Business Unit Head Commercial Ops., Sanofi Germany |
| 2014-2015 | Country Manager, Sanofi |
| 2016-2017 | Country Chair and General Manager DVC&GEM, Sanofi |
| 2018 | General Manager GenMed Austria&Switzerland and Country Chair Austria, Sanofi |
| since 2019 | Commercial Head Established Products Mature Markets at Sanofi |
Emilio GALLI-ZUGARO
Chairman, Methodos S.p.A., Milan; Founder, Orvieto Academy for Communicative Leadership, Munich/Orvieto
| Studied Political Sciences in Würzburg and Rome | |
| 1980-1985 | Communcation functions in public service, Rome |
| 1985-1992 | Journalist for FORTUNE, Wirtschaftswoche, L'Independente, Italia Oggi, Il Giornale, Finanz und Wirtschaft, The European |
| since 1996 | Author and Scholar, Ludwig-Maximilians-University, Munich |
| since 2000 | European School of Management and Technology, Berlin |
| 1992-2015 | Head of Group Communications, Allianz SE, Munich |
| since 2015 | Chairman of Methodos, S.p.A., Milan |
| Executive coach and mentor, Entrepreneurship Center, Munich | |
| since 2017 | Founder, Orvieto Academy for Communicative Leadership, Orvieto |
